Bio Green Med Solution Inc Financials
This page shows Bio Green Med Solution Inc (BGMS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 27 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Bio Green Med Solution Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Bio Green Med Solution Inc generates $0.71 in operating cash flow (-$8.0M OCF vs -$11.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Bio Green Med Solution Inc generated $43K in revenue in fiscal year 2024. This represents a decrease of 89.8% from the prior year.
Bio Green Med Solution Inc's EBITDA was -$12.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.8% from the prior year.
Bio Green Med Solution Inc reported -$11.2M in net income in fiscal year 2024. This represents an increase of 50.3% from the prior year.
Bio Green Med Solution Inc earned $-0.50 per diluted share (EPS) in fiscal year 2024. This represents an increase of 92.1% from the prior year.
Bio Green Med Solution Inc held $3.1M in cash against $0 in long-term debt as of fiscal year 2024.
Bio Green Med Solution Inc had 36,913 shares outstanding in fiscal year 2024. This represents an increase of 736.7% from the prior year.
Bio Green Med Solution Inc's operating margin was -27916.3% in fiscal year 2024, reflecting core business profitability. This is down 21856.0 percentage points from the prior year.
Bio Green Med Solution Inc's net profit margin was -26074.4% in fiscal year 2024, showing the share of revenue converted to profit. This is down 20704.2 percentage points from the prior year.
Bio Green Med Solution Inc invested $6.7M in research and development in fiscal year 2024. This represents a decrease of 65.3% from the prior year.
BGMS Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81K-77.2% | $356K-10.1% | $396K | $0-100.0% | $10K+150.0% | $4K-86.2% | $29K | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5K-92.6% | $68K-91.7% | $822K-6.6% | $880K-7.4% | $950K-53.0% | $2.0M-27.8% | $2.8M | N/A |
| SG&A Expenses | $1.0M-19.6% | $1.2M-70.4% | $4.2M+344.5% | $948K-23.4% | $1.2M-23.9% | $1.6M+2.7% | $1.6M | N/A |
| Operating Income | -$992K+24.7% | -$1.3M+73.8% | -$5.0M-175.5% | -$1.8M+16.0% | -$2.2M+40.3% | -$3.6M+16.3% | -$4.4M | N/A |
| Interest Expense | $9K+350.0% | $2K-66.7% | $6K | N/A | $8K+128.6% | -$28K-1500.0% | $2K | N/A |
| Income Tax | -$750K-37600.0% | $2K+100.4% | -$569K-147.7% | $1.2M+668.6% | -$210K+49.0% | -$412K+69.6% | -$1.4M | N/A |
| Net Income | -$988K+25.0% | -$1.3M-1527.2% | -$81K+97.3% | -$3.1M-56.0% | -$2.0M+39.9% | -$3.3M-10.6% | -$2.9M | N/A |
| EPS (Diluted) | $-1.31-33.7% | $-0.98 | $0.00 | N/A | $-43.80 | $-172.18-7485.0% | $-2.27 | N/A |
BGMS Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.2M+85.4% | $4.4M+17.9% | $3.7M-8.8% | $4.1M-23.9% | $5.4M-34.3% | $8.2M+32.8% | $6.2M-30.0% | $8.8M |
| Current Assets | $6.4M+47.0% | $4.4M+18.0% | $3.7M+1.1% | $3.7M-25.2% | $4.9M-36.3% | $7.7M+59.4% | $4.8M-35.0% | $7.4M |
| Cash & Equivalents | $3.8M-10.2% | $4.3M+23.9% | $3.5M+10.0% | $3.1M+5.2% | $3.0M-50.3% | $6.0M+114.4% | $2.8M-17.2% | $3.4M |
| Inventory | $1.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $725K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.1M+37.9% | $770K+14.6% | $672K-89.3% | $6.3M-1.3% | $6.4M-11.7% | $7.2M-14.1% | $8.4M+2.1% | $8.2M |
| Current Liabilities | $1.0M+31.8% | $760K+14.6% | $663K-89.4% | $6.3M-1.3% | $6.4M-11.6% | $7.2M-13.9% | $8.3M+2.3% | $8.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.1M+95.4% | $3.6M+18.6% | $3.1M+240.8% | -$2.2M-124.1% | -$970K-197.1% | $999K+145.3% | -$2.2M-463.4% | $607K |
| Retained Earnings | -$444.3M-0.6% | -$441.8M-0.3% | -$440.5M-0.2% | -$439.5M-0.7% | -$436.4M-0.5% | -$434.5M-0.8% | -$431.2M-0.7% | -$428.3M |
BGMS Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$434K+58.9% | -$1.1M+67.5% | -$3.2M-139.5% | -$1.4M+55.8% | -$3.1M+0.6% | -$3.1M-538.5% | -$483K+87.6% | -$3.9M |
| Capital Expenditures | $237K+597.1% | $34K+9.7% | $31K+933.3% | $3K | $0-100.0% | $1K-50.0% | $2K | $0 |
| Free Cash Flow | -$6.4M-55.8% | -$4.1M+13.1% | -$4.8M-324.7% | -$1.1M+63.5% | -$3.1M-16.4% | -$2.6M+28.5% | -$3.7M+5.7% | -$3.9M |
| Investing Cash Flow | N/A | N/A | N/A | $6K | $0+100.0% | -$1K-103.7% | $27K | $0 |
| Financing Cash Flow | -$3K-100.2% | $1.9M-48.4% | $3.6M+126.0% | $1.6M+161400.0% | -$1K-100.0% | $6.3M+8060.8% | -$79K-107.9% | $999K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BGMS Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1224.7%+341.3pp | -1566.0%-199.8pp | -1366.2%-37.1pp | -1329.1%+20440.9pp | -21770.0%+69330.0pp | -91100.0%-76082.8pp | -15017.2% | N/A |
| Net Margin | -1219.8%+131.9pp | -1351.7%-122.1pp | -1229.5%-39.3pp | -1190.3%+18379.7pp | -19570.0%+61855.0pp | -81425.0%-71266.4pp | -10158.6% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | 4.8% | N/A | N/A |
| Return on Assets | -12.1%+17.8pp | -29.9%-27.8pp | -2.2%+72.4pp | -74.6%-38.2pp | -36.4%+3.4pp | -39.8%+8.0pp | -47.8% | N/A |
| Current Ratio | 6.43+0.7 | 5.77+0.2 | 5.60+5.0 | 0.59-0.2 | 0.77-0.3 | 1.07+0.5 | 0.58-0.3 | 0.91 |
| Debt-to-Equity | 0.15-0.1 | 0.210.0 | 0.22+3.1 | -2.88+3.7 | -6.55-13.7 | 7.20+11.0 | -3.79-17.3 | 13.51 |
| FCF Margin | -876.7%+284.8pp | -1161.5%+39.7pp | -1201.3%+633.9pp | -1835.1%+28834.9pp | -30670.0%-28657.1pp | -2012.9%+562.6pp | -2575.5% | N/A |
Note: Shareholder equity is negative (-$2.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.59), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is Bio Green Med Solution Inc's annual revenue?
Bio Green Med Solution Inc (BGMS) reported $43K in total revenue for fiscal year 2024. This represents a -89.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bio Green Med Solution Inc's revenue growing?
Bio Green Med Solution Inc (BGMS) revenue declined by 89.8% year-over-year, from $420K to $43K in fiscal year 2024.
Is Bio Green Med Solution Inc profitable?
No, Bio Green Med Solution Inc (BGMS) reported a net income of -$11.2M in fiscal year 2024, with a net profit margin of -26074.4%.
What is Bio Green Med Solution Inc's earnings per share (EPS)?
Bio Green Med Solution Inc (BGMS) reported diluted earnings per share of $-0.50 for fiscal year 2024. This represents a 92.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Bio Green Med Solution Inc's EBITDA?
Bio Green Med Solution Inc (BGMS) had EBITDA of -$12.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bio Green Med Solution Inc's operating margin?
Bio Green Med Solution Inc (BGMS) had an operating margin of -27916.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Bio Green Med Solution Inc's net profit margin?
Bio Green Med Solution Inc (BGMS) had a net profit margin of -26074.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Bio Green Med Solution Inc's operating cash flow?
Bio Green Med Solution Inc (BGMS) generated -$8.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Bio Green Med Solution Inc's total assets?
Bio Green Med Solution Inc (BGMS) had $4.1M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Bio Green Med Solution Inc spend on research and development?
Bio Green Med Solution Inc (BGMS) invested $6.7M in research and development during fiscal year 2024.
How many shares does Bio Green Med Solution Inc have outstanding?
Bio Green Med Solution Inc (BGMS) had 36,913 shares outstanding as of fiscal year 2024.
What is Bio Green Med Solution Inc's current ratio?
Bio Green Med Solution Inc (BGMS) had a current ratio of 0.59 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Bio Green Med Solution Inc's debt-to-equity ratio?
Bio Green Med Solution Inc (BGMS) had a debt-to-equity ratio of -2.88 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bio Green Med Solution Inc's return on assets (ROA)?
Bio Green Med Solution Inc (BGMS) had a return on assets of -273.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Bio Green Med Solution Inc's cash runway?
Based on fiscal year 2024 data, Bio Green Med Solution Inc (BGMS) had $3.1M in cash against an annual operating cash burn of $8.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Bio Green Med Solution Inc's debt-to-equity ratio negative or unusual?
Bio Green Med Solution Inc (BGMS) has negative shareholder equity of -$2.2M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Bio Green Med Solution Inc's Piotroski F-Score?
Bio Green Med Solution Inc (BGMS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio Green Med Solution Inc's earnings high quality?
Bio Green Med Solution Inc (BGMS) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.